Clinical Value of Asymmetrical Dimethylarginine Detection in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

Table 2

Comparison of echocardiography and pulmonary function in patients with CTD.

Parameters	Normal sPAP (n = 45)	Abnormal sPAP (N = 43)	value
sPAP (M(QR), mmHg)	23.0 (18.0, 28.0)	51.0 (46.0, 54.0)	<0.001
EF (M(QR), %)	59.0 (51.0, 65.5)	60.0 (56.0, 65.0)	0.287
CO (, L)	4.2 (3.1, 4.9)	4.1 (3.7, 5.4)	0.619
VC% (, %)	83.51 ± 17.98	72.80 ± 19.05	0.012
FVC% (, %)	83.35 ± 17.13	73.20 ± 19.51	0.016
FEV1/FVC (, %)	92.36 ± 8.25	90.28 ± 9.59	0.304
RV% (M(QR), %)	99.0 (90.0, 105.0)	103.0 (96.5, 111.0)	0.063
DLCO% (, %)	72.28 ± 20.97	53.92 ± 19.37	<0.001

; sPAP = pulmonary arterial systolic pressure; EF = ejection fraction; CO = cardiac output; VC% = percentage of vital capacity to the estimated value; FVC% = percentage of forced vital capacity to the estimated value; FEV1/FVC = forced the first second of expiratory volume/forced vital capacity; RV% = percentage of residual gas to the estimated value; DLCO% = percentage of diffusing capacity for carbon monoxide to the estimated value.